2000
Imaging extrastriatal dopamine D2 receptor occupancy by endogenous dopamine in healthy humans
Fujita M, Verhoeff N, Varrone A, Zoghbi S, Baldwin R, Jatlow P, Anderson G, Seibyl J, Innis R. Imaging extrastriatal dopamine D2 receptor occupancy by endogenous dopamine in healthy humans. European Journal Of Pharmacology 2000, 387: 179-188. PMID: 10650158, DOI: 10.1016/s0014-2999(99)00817-1.Peer-Reviewed Original ResearchConceptsAcute dopamine depletionDopamine depletionEndogenous dopamineAlpha-methylTemporal cortexExtrastriatal dopamine D2 receptor occupancyDopamine D2 receptor occupancyD2 receptor occupancySynaptic dopamine concentrationsSingle photon emissionNegative Symptom ScalePara-tyrosineExtrastriatal regionsOral administrationHealthy humansSymptom ScaleReceptor occupancyDopamine concentrationsDysphoric moodDopaminePhoton emissionHigh-affinity ligandsCortexVivo measurementsThalamus
1993
Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: A pilot study
Chappell P, Leckman J, Scahill L, Hardin M, Anderson G, Cohen D. Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: A pilot study. Psychiatry Research 1993, 47: 267-280. PMID: 8396784, DOI: 10.1016/0165-1781(93)90084-t.Peer-Reviewed Original ResearchConceptsNormal control subjectsTourette syndromeTic frequencyControl subjectsTS patientsMicrograms/Clinician ratingsKappa agonist spiradolineInvolvement of opioidRole of opioidsGrowth hormone secretionDual modulatory effectsDose-response studyMotor tic frequencyMore growth hormoneTic symptomsHormone secretionNeuroendocrine effectsKappa receptorsPhonic ticsSpiradoline mesylateIntermediate doseLow doseModulatory effectsSpiradoline